Amicus Therapeutics, Inc. (FOLD), a biotechnology company, on Monday reported higher preliminary revenue for fiscal 2023.
Yearly revenue increased 21 percent to around $399.4 million from $329 million.
Sequentially, revenue increased to around $399.4 million from $115.1 million in the fourth quarter.
The pharma firm's lead drug Galafold recorded a net sale of around $387.8 million representing a year-over-year increase of 18 percent.
Further, the company said it sees delivering double-digit Galafold revenue growth in the range of 11 percent to 16 percent at constant exchange rates for the full year.
On Friday, Amicus shares closed at $13.75, up 1.70% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.